Health Medical Breakthroughs Treatment

New Crohn’s Disease Research Findings: Crohn’s disease risk and prognosis determined by different genes, study finds

Posted on Posted in Crohn's Disease News

(SOURCE: UNIVERSITY OF CAMBRIDGE) – Researchers have identified a series of genetic variants that affect the severity of Crohn’s disease, an inflammatory bowel disease – but surprisingly, none of these variants appear to be related to an individual’s risk of developing the condition in the first place. Crohn’s disease is one of a number of chronic ‘complex’ […]

Health Medical Breakthroughs Treatment

New Crohn’s Disease Treatment Research: Testing a New Treatment for Crohn’s Disease

Posted on Posted in Crohn's Disease News

(SOURCE: NORTHWESTERN UNIVERSITY) – Patients with moderate to severe Crohn’s disease showed significant improvement on a drug called ustekinumab, according to the results of phase III clinical trials published in the New England Journal of Medicine. The study was co-authored by Stephen Hanauer, MD, the Clifford Joseph Barborka Professor of Medicine in the Division of Gastroenterology […]

Health Medical Breakthroughs Treatment

High Levels of Certain Bacteria and Fungus May Be Contributor Crohn’s Disease

Posted on Posted in Crohn's Disease News

(Scientific American) According to a recent article published in Scientific American, a new study finds that two types of bacteria, called Escherichia coli and Serratia marcescens, and one fungus, called Candida tropicalis, may may not only play a role in the development of Crohn’s disease, but may also play a role in the condition. According to the article, the findings could […]

Health Medical Breakthroughs Treatment

FDA Approval of STELARA® Seen as Important Advancement in Treating Patients with Crohn’s Disease

Posted on Posted in Crohn's Disease News

(PR Newswire) Janssen Biotech, Inc., recently announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of moderately to severely active Crohn’s disease in adults (18 years or older) who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a tumor necrosis factor […]